Andrej Ozaniak

TL;DR: A review of the most promising TRAIL-based clinical trials and their therapeutic strategies is presented in this article, where the current status of all TRAILbased monotherapies and combination therapies that have reached phase II and phase III clinical trials in humans.

TL;DR: In this article, the authors introduce the most important immune cell types infiltrating the soft tissue sarcomas tumors and discuss different immunotherapies, as well as promising clinical trials, that would target these immune cells to enhance the antitumor immune responses and improve the prognosis of metastatic STSs patients.

TL;DR: An improved understanding of the complex LPS immune contexture enables the design and refinement of novel immunotherapeutic approaches and highlights differences between the LPS subtypes that may have implications for the design of novel treatment strategies.

TL;DR: Both anti-PD-1 and anti-CD47 therapies drastically increased the production of pro-inflammatory cytokines in the tumor microenvironment of STSs, but co-administration of both agents did not further increase cytokine secretion.